A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis
In this phase 2 placebo-controlled trial, peresolimab, a humanized monoclonal antibody that stimulates the programmed cell death protein 1 inhibitory pathway, showed efficacy in adults with rheumatoid arthritis.
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2023-05, Vol.388 (20), p.1853-1862 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1862 |
|---|---|
| container_issue | 20 |
| container_start_page | 1853 |
| container_title | The New England journal of medicine |
| container_volume | 388 |
| creator | Tuttle, Jay Drescher, Edit Simón-Campos, Jesus Abraham Emery, Paul Greenwald, Maria Kivitz, Alan Rha, Hyungmin Yachi, Pia Kiley, Christina Nirula, Ajay |
| description | In this phase 2 placebo-controlled trial, peresolimab, a humanized monoclonal antibody that stimulates the programmed cell death protein 1 inhibitory pathway, showed efficacy in adults with rheumatoid arthritis. |
| doi_str_mv | 10.1056/NEJMoa2209856 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2815248273</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2814935466</sourcerecordid><originalsourceid>FETCH-LOGICAL-c351t-ba5e2b917fbed1f40f8b0f93ba3bc624b976326a8eb7c86ac407c07a9607111e3</originalsourceid><addsrcrecordid>eNp10NtLwzAUBvAgipvTR18lIIIv1dzTPJYxb3gZMp9L0ia0o11m0iL-93ZsCgqel_Py4-OcD4BTjK4w4uL6efbw5DUhSKVc7IEx5pQmjCGxD8YIkTRhUtEROIpxiYbBTB2CEZVYccXwGEwzOK90tJDARah1A72Dcxts9E3dagOdDzAr-6aL8KPuKvha2b7Vna9LmIWuCnVXx2Nw4HQT7cluT8DbzWwxvUseX27vp9ljUlCOu8RobolRWDpjS-wYcqlBTlGjqSkEYUZJQYnQqTWySIUuGJIFkloJJDHGlk7A5TZ3Hfx7b2OXt3UsbNPolfV9zEmKOWEpkXSg53_o0vdhNVy3UUxRzoQYVLJVRfAxBuvydRi-Dp85Rvmm3fxXu4M_26X2prXlj_6ucwAXW9C2MV_ZZftP0Bcz5X5v</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2814935466</pqid></control><display><type>article</type><title>A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Tuttle, Jay ; Drescher, Edit ; Simón-Campos, Jesus Abraham ; Emery, Paul ; Greenwald, Maria ; Kivitz, Alan ; Rha, Hyungmin ; Yachi, Pia ; Kiley, Christina ; Nirula, Ajay</creator><creatorcontrib>Tuttle, Jay ; Drescher, Edit ; Simón-Campos, Jesus Abraham ; Emery, Paul ; Greenwald, Maria ; Kivitz, Alan ; Rha, Hyungmin ; Yachi, Pia ; Kiley, Christina ; Nirula, Ajay</creatorcontrib><description>In this phase 2 placebo-controlled trial, peresolimab, a humanized monoclonal antibody that stimulates the programmed cell death protein 1 inhibitory pathway, showed efficacy in adults with rheumatoid arthritis.</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa2209856</identifier><identifier>PMID: 37195941</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Administration, Intravenous ; Adult ; Allergy ; Antibodies, Monoclonal, Humanized - administration & dosage ; Antibodies, Monoclonal, Humanized - adverse effects ; Antibodies, Monoclonal, Humanized - therapeutic use ; Antirheumatic Agents - administration & dosage ; Antirheumatic Agents - adverse effects ; Antirheumatic Agents - therapeutic use ; Apoptosis ; Arthritis, Rheumatoid - diagnosis ; Arthritis, Rheumatoid - drug therapy ; Autoimmune Disease ; C-reactive protein ; Cell death ; Disease ; Double-Blind Method ; Drug Therapy, Combination ; Homeostasis ; Humans ; Immunoglobulin G ; Immunology ; Immunology General ; Inflammatory Disease ; Inflammatory diseases ; Joint diseases ; Lymphocytes ; Magnetic resonance imaging ; Monoclonal antibodies ; Pathogenesis ; Patients ; PD-1 protein ; Placebos ; Programmed Cell Death 1 Receptor - agonists ; Proteins ; Remission (Medicine) ; Rheumatoid Arthritis ; Rheumatology ; Rheumatology General ; Severity of Illness Index ; T-Cells ; Treatment Outcome</subject><ispartof>The New England journal of medicine, 2023-05, Vol.388 (20), p.1853-1862</ispartof><rights>Copyright © 2023 Massachusetts Medical Society. All rights reserved.</rights><rights>Copyright © 2023 Massachusetts Medical Society.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c351t-ba5e2b917fbed1f40f8b0f93ba3bc624b976326a8eb7c86ac407c07a9607111e3</citedby><cites>FETCH-LOGICAL-c351t-ba5e2b917fbed1f40f8b0f93ba3bc624b976326a8eb7c86ac407c07a9607111e3</cites><orcidid>0000-0001-9630-7792</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa2209856$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2814935466?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>315,781,785,2760,2761,26108,27929,27930,52387,54069,64390,64392,64394,72474</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37195941$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tuttle, Jay</creatorcontrib><creatorcontrib>Drescher, Edit</creatorcontrib><creatorcontrib>Simón-Campos, Jesus Abraham</creatorcontrib><creatorcontrib>Emery, Paul</creatorcontrib><creatorcontrib>Greenwald, Maria</creatorcontrib><creatorcontrib>Kivitz, Alan</creatorcontrib><creatorcontrib>Rha, Hyungmin</creatorcontrib><creatorcontrib>Yachi, Pia</creatorcontrib><creatorcontrib>Kiley, Christina</creatorcontrib><creatorcontrib>Nirula, Ajay</creatorcontrib><title>A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>In this phase 2 placebo-controlled trial, peresolimab, a humanized monoclonal antibody that stimulates the programmed cell death protein 1 inhibitory pathway, showed efficacy in adults with rheumatoid arthritis.</description><subject>Administration, Intravenous</subject><subject>Adult</subject><subject>Allergy</subject><subject>Antibodies, Monoclonal, Humanized - administration & dosage</subject><subject>Antibodies, Monoclonal, Humanized - adverse effects</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Antirheumatic Agents - administration & dosage</subject><subject>Antirheumatic Agents - adverse effects</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Apoptosis</subject><subject>Arthritis, Rheumatoid - diagnosis</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Autoimmune Disease</subject><subject>C-reactive protein</subject><subject>Cell death</subject><subject>Disease</subject><subject>Double-Blind Method</subject><subject>Drug Therapy, Combination</subject><subject>Homeostasis</subject><subject>Humans</subject><subject>Immunoglobulin G</subject><subject>Immunology</subject><subject>Immunology General</subject><subject>Inflammatory Disease</subject><subject>Inflammatory diseases</subject><subject>Joint diseases</subject><subject>Lymphocytes</subject><subject>Magnetic resonance imaging</subject><subject>Monoclonal antibodies</subject><subject>Pathogenesis</subject><subject>Patients</subject><subject>PD-1 protein</subject><subject>Placebos</subject><subject>Programmed Cell Death 1 Receptor - agonists</subject><subject>Proteins</subject><subject>Remission (Medicine)</subject><subject>Rheumatoid Arthritis</subject><subject>Rheumatology</subject><subject>Rheumatology General</subject><subject>Severity of Illness Index</subject><subject>T-Cells</subject><subject>Treatment Outcome</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp10NtLwzAUBvAgipvTR18lIIIv1dzTPJYxb3gZMp9L0ia0o11m0iL-93ZsCgqel_Py4-OcD4BTjK4w4uL6efbw5DUhSKVc7IEx5pQmjCGxD8YIkTRhUtEROIpxiYbBTB2CEZVYccXwGEwzOK90tJDARah1A72Dcxts9E3dagOdDzAr-6aL8KPuKvha2b7Vna9LmIWuCnVXx2Nw4HQT7cluT8DbzWwxvUseX27vp9ljUlCOu8RobolRWDpjS-wYcqlBTlGjqSkEYUZJQYnQqTWySIUuGJIFkloJJDHGlk7A5TZ3Hfx7b2OXt3UsbNPolfV9zEmKOWEpkXSg53_o0vdhNVy3UUxRzoQYVLJVRfAxBuvydRi-Dp85Rvmm3fxXu4M_26X2prXlj_6ucwAXW9C2MV_ZZftP0Bcz5X5v</recordid><startdate>20230518</startdate><enddate>20230518</enddate><creator>Tuttle, Jay</creator><creator>Drescher, Edit</creator><creator>Simón-Campos, Jesus Abraham</creator><creator>Emery, Paul</creator><creator>Greenwald, Maria</creator><creator>Kivitz, Alan</creator><creator>Rha, Hyungmin</creator><creator>Yachi, Pia</creator><creator>Kiley, Christina</creator><creator>Nirula, Ajay</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9630-7792</orcidid></search><sort><creationdate>20230518</creationdate><title>A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis</title><author>Tuttle, Jay ; Drescher, Edit ; Simón-Campos, Jesus Abraham ; Emery, Paul ; Greenwald, Maria ; Kivitz, Alan ; Rha, Hyungmin ; Yachi, Pia ; Kiley, Christina ; Nirula, Ajay</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c351t-ba5e2b917fbed1f40f8b0f93ba3bc624b976326a8eb7c86ac407c07a9607111e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Administration, Intravenous</topic><topic>Adult</topic><topic>Allergy</topic><topic>Antibodies, Monoclonal, Humanized - administration & dosage</topic><topic>Antibodies, Monoclonal, Humanized - adverse effects</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Antirheumatic Agents - administration & dosage</topic><topic>Antirheumatic Agents - adverse effects</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Apoptosis</topic><topic>Arthritis, Rheumatoid - diagnosis</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Autoimmune Disease</topic><topic>C-reactive protein</topic><topic>Cell death</topic><topic>Disease</topic><topic>Double-Blind Method</topic><topic>Drug Therapy, Combination</topic><topic>Homeostasis</topic><topic>Humans</topic><topic>Immunoglobulin G</topic><topic>Immunology</topic><topic>Immunology General</topic><topic>Inflammatory Disease</topic><topic>Inflammatory diseases</topic><topic>Joint diseases</topic><topic>Lymphocytes</topic><topic>Magnetic resonance imaging</topic><topic>Monoclonal antibodies</topic><topic>Pathogenesis</topic><topic>Patients</topic><topic>PD-1 protein</topic><topic>Placebos</topic><topic>Programmed Cell Death 1 Receptor - agonists</topic><topic>Proteins</topic><topic>Remission (Medicine)</topic><topic>Rheumatoid Arthritis</topic><topic>Rheumatology</topic><topic>Rheumatology General</topic><topic>Severity of Illness Index</topic><topic>T-Cells</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tuttle, Jay</creatorcontrib><creatorcontrib>Drescher, Edit</creatorcontrib><creatorcontrib>Simón-Campos, Jesus Abraham</creatorcontrib><creatorcontrib>Emery, Paul</creatorcontrib><creatorcontrib>Greenwald, Maria</creatorcontrib><creatorcontrib>Kivitz, Alan</creatorcontrib><creatorcontrib>Rha, Hyungmin</creatorcontrib><creatorcontrib>Yachi, Pia</creatorcontrib><creatorcontrib>Kiley, Christina</creatorcontrib><creatorcontrib>Nirula, Ajay</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database (ProQuest)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tuttle, Jay</au><au>Drescher, Edit</au><au>Simón-Campos, Jesus Abraham</au><au>Emery, Paul</au><au>Greenwald, Maria</au><au>Kivitz, Alan</au><au>Rha, Hyungmin</au><au>Yachi, Pia</au><au>Kiley, Christina</au><au>Nirula, Ajay</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2023-05-18</date><risdate>2023</risdate><volume>388</volume><issue>20</issue><spage>1853</spage><epage>1862</epage><pages>1853-1862</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>In this phase 2 placebo-controlled trial, peresolimab, a humanized monoclonal antibody that stimulates the programmed cell death protein 1 inhibitory pathway, showed efficacy in adults with rheumatoid arthritis.</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>37195941</pmid><doi>10.1056/NEJMoa2209856</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-9630-7792</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2023-05, Vol.388 (20), p.1853-1862 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2815248273 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Administration, Intravenous Adult Allergy Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Antirheumatic Agents - administration & dosage Antirheumatic Agents - adverse effects Antirheumatic Agents - therapeutic use Apoptosis Arthritis, Rheumatoid - diagnosis Arthritis, Rheumatoid - drug therapy Autoimmune Disease C-reactive protein Cell death Disease Double-Blind Method Drug Therapy, Combination Homeostasis Humans Immunoglobulin G Immunology Immunology General Inflammatory Disease Inflammatory diseases Joint diseases Lymphocytes Magnetic resonance imaging Monoclonal antibodies Pathogenesis Patients PD-1 protein Placebos Programmed Cell Death 1 Receptor - agonists Proteins Remission (Medicine) Rheumatoid Arthritis Rheumatology Rheumatology General Severity of Illness Index T-Cells Treatment Outcome |
| title | A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T01%3A59%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Phase%202%20Trial%20of%20Peresolimab%20for%20Adults%20with%20Rheumatoid%20Arthritis&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Tuttle,%20Jay&rft.date=2023-05-18&rft.volume=388&rft.issue=20&rft.spage=1853&rft.epage=1862&rft.pages=1853-1862&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMoa2209856&rft_dat=%3Cproquest_cross%3E2814935466%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2814935466&rft_id=info:pmid/37195941&rfr_iscdi=true |